Is Wegovy better than Foundayo?

There is no single answer. The right medicine depends on your health, other medicines, preferences (such as injection or tablet) and how you respond. Clinical trials of each medicine used different designs, so comparing headline results needs care. A prescriber can help you weigh up the options.

Can I switch from Wegovy to Foundayo?

Switching between GLP-1 medicines is possible but should only be done under the supervision of a prescriber, who will decide the starting dose of the new medicine and the timing. Do not take both at the same time, and do not switch on your own.

Wegovy vs Foundayo: how they compare

Wegovy (semaglutide) and Foundayo (orforglipron) compared side by side: how they work, dosing, side effects and UK status.

Key differences

Wegovy is a GLP-1 receptor agonist, while Foundayo is a non-peptide (small-molecule) GLP-1 receptor agonist.
Wegovy is an injection; Foundayo is a tablet.
Wegovy is taken once a week, whereas Foundayo is taken once a day.

Side-by-side

Comparison of Wegovy, Foundayo
Attribute	Wegovy	Foundayo
Active ingredient	semaglutide	orforglipron
Drug class	GLP-1 receptor agonist	Non-peptide (small-molecule) GLP-1 receptor agonist
Manufacturer	Novo Nordisk	Eli Lilly
Form	Injection	Tablet
How often	once a week	once a day
Device	FlexTouch pen	None (tablet)
Starting dose	0.25mg	0.8mg
Dose range	0.25mg to 7.2mg	0.8mg to 17.2mg
UK status	Licensed in the UK for weight management	Licensed in the UK for weight management
NICE guidance	NICE TA875 (March 2023)	Not yet verified
Common side effects	Nausea, Diarrhoea, Constipation, Vomiting, Indigestion and reflux, Injection site reactions	Nausea, Diarrhoea, Constipation, Vomiting, Indigestion and reflux

Wegovy vs Foundayo: how they compare

Key differences

Side-by-side

Frequently asked questions

Comparison guides